Compounds and compositions for the inhibition of NAMPT

1. A compound of Formula IB:

wherein:

Ar is aryl or heteroaryl, each of said aryl and heteroaryl being either unsubstituted or optionally independently substituted with 1, 2, 3, or 4 substituents which can be the same or different and are independently selected from the group consisting of:

deuterium, halo, cyano, amino, aminoalkyl-, (amino)alkoxy-, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CH z F 3-z , —OCH z F 3-z , -alkyl, -alkenyl, -alkynyl, -alkoxy, (alkoxyalkyl)amino-, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

R 1 is —NR a R b , wherein R a is H, alkyl, or —S(O) 2 alkyl and R b is alkyl, hydroxyalkyl, —S(O) 2 alkyl, —(CH 2 ) q cycloalkyl, —(CH 2 ) q heterocycloalkyl, aryl, arylalkyl-, —(CH 2 ) q heteroaryl;

cycloalkyl;

heterocycloalkyl;

aryl;

heteroaryl;

each of said cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents which can be the same or different and are independently selected from the group consisting of:

deuterium, halo, cyano, alkyl, hydroxyl, hydroxyalkyl, hydroxyalkoxy, cyanoalkyl, haloalkyl, alkenyl, alkynyl, alkoxy, alkylalkoxy, haloalkoxy, arylalkenyl-, aryloxy, benzyloxy, oxo, —(CH 2 ) q —NR c R d , —(CH 2 ) q —CONR c R d , —S(O) 2 -alkyl, —S(O) 2 -aryl, S(O) 2 NH 2 , —S(O) 2 NH-alkyl, —S(O) 2 N(alkyl) 2 , —S(O) 2 -heterocycloalkyl, —S(O) 2 —CF 3 , —C(O)alkyl, —C(O)aryl, —C(O)alkylenylaryl, —C(O)O-alkyl, —NH—C(O)alkyl, —NH—C(O)aryl, methylenedioxy, —(CH 2 ) q cycloalkyl, cycloalkylalkoxy-, aryl, arylalkyl-, —(CH 2 ) q heteroaryl, and —(CH 2 ) q heterocycloalkyl,

wherein each of said cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be substituted by one or more halo, nitro, haloalkyl, haloalkoxy, oxo, cyano, alkyl, haloalkyl, or alkoxy and;

R c and R d are independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxy, aryl, alkoxyalkyl, —S(O) 2 alkyl and cycloalkyl or R C and R d can form a 5 or 6 membered heterocycloalkyl group together with the nitrogen atom to which they are attached, wherein said heterocycloalkyl group may contain one or more addional heteroatom(s) selected from N, S or O;

z is 0, 1 or 2;

q is 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof, with the proviso that the compound of formula IB is not:

N-[3-(cyclopentylsulfonyl)phenyl]-3-(3-pyridinyl)-2-propenamide;

N-[4-ethoxy-3-(4-morpholinylsulfonyl)phenyl]-3-(3-pyridinyl)-2-propenamide;

N-[2-(1-methylethoxy)-5-(4-morpholinylsulfonyl)phenyl]-3-(3-pyridinyl)-2-propenamide;

N-[2-ethoxy-5-(4-morpholinylsulfonyl)phenyl]-3-(3-pyridinyl)-2-propenamide;

N-[5-[(hexahydro-1Hazepin-1-yl)sulfonyl]-2-(2,2,2-trifluoroethoxy)phenyl]-3-(3-pyridinyl)-2-propenamide;

N-[5-[(diethylamino)sulfonyl]-2-(4-morpholinyl)phenyl]-3-(3-pyridinyl)-2-propenamide;

N-[3-[[(3-chlorophenyl)amino]sulfonyl]-4-methylphenyl]-3-(3-pyridinyl)-2-propenamide;

N-[3-[[(4-chlorophenyl)amino]sulfonyl]-4-methylphenyl]-3-(3-pyridinyl)-2-propenamide;

3-(3-pyridinyl)-N-[4-[[(tetrahydro-1,1-dioxido-3-thienyl)amino]sulfonyl]phenyl]-2-propenamide;

3-(3-pyridinyl)-N-[3-[[[3-(trifluoromethyl)phenyl]amino]sulfonyl]phenyl]-2-propenamide; or 3-(3-pyridinyl)-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-2-propenamide.

2. The compound of claim 1 , wherein Ar is aryl.

3. The compound of claim 1 , wherein Ar is phenyl.

4. The compound of claim 1 , wherein Ar is:

5. The compound of claim 1 , wherein R 1 is —NR a R b .

6. The compound of claim 5 , wherein R a is H, C 1 -C 6 -alkyL or —S(O) 2 —C 1 -C 6 -alkyl, and R b is C 1-C 6 -alkyl, hydroxyl-C 1 -C 6 -alkyl, —S(O) 2 -C 1-C 6 -alkyl, —(CH 2 ) q —C 3 -C6-cycloalkyl, —(CH 2 ) q heterocycloalkyl, phenyl, phenylalkyl-, or —(CH 2 ) q heteroaryl, wherein heterocycloalkyl groups are 5 or 6 membered heterocycloalkyl groups containing 1, 2, or 3 heteroatoms selected from the group consisting of N, O, and S and wherein heteroaryl groups are 5 or 6 membered heteroaryl groups containing 1, 2, or 3 heteroatoms selected from the group consisting of N, O, and S.

7. The compound of claim 1 , wherein R 1 is cycloalkyl.

8. The compound of claim 1 , wherein R 1 is aryl.

9. The compound of claim 1 , wherein R 1 is heterocycloalkyl.

10. The compound of claim 1 , wherein R 1 is heteroaryl.

11. The compound of claim 1 , wherein R 1 is a 5 to 14 membered monocyclic or bicyclic heteroaryl group containing 1, 2, or 3 heteroatoms selected from the group consisting of N, O, and S.

12. The compound of claim 1 , wherein R 1 is selected from the group consisting of: pyridine, pyrazole, thiophene, pyrimidine, 1H-indole, quinoline, isoquinoline, 1H-indazole, benzothiophene, phenoxathiine, 2H-1,3-benzodioxole, 2,3-dihydro-l-benzofuran, and 8-oxatricyclo[7.4.0.0 2 , 7 ]trideca-1(13),2,4,6,9,11-hexaene.

13. The compound of claim 1 , wherein R 1 is selected from the group consisting of:

(1H-pyrazol-1-yl)benzene; 1-benzothiophene; 1H-indole; 1-methyl-1H-indazole; 1-methyl-1H -indole; 1-methyl-1H-pyrazole; 2-(dimethylamino)pyrimidine; 2-(morpholin-4-yl)pyridine; 2-(trifluoromethoxy)benzene; 2,3-dihydro-1-benzofuran; 2,5-dichlorobenzene; 2-chloro-5-(trifluoromethoxy)benzene; 2H-1,3-benzodioxole; 2-methoxy-4-(trifluoromethyl)benzene; 2-methoxy-5-(propan-2-yl)benzene; 2-methoxy-5-(trifluoromethoxy)benzene; 2-methoxy-5-(trifluoromethyl)benzene; 2-methoxy-5-methylbenzene; 2-methoxybenzene; 2-methyl-4-(trifluoromethyl)benzene; 2-methylbenzene; 3-(2-methylpropoxy)benzene; 3-(3,5-dimethyl-1H-pyrazol-1-yl)benzene; 3-(ethanesulfonyl)benzene; 3-(methoxymethyl)benzene; 3-(morpholin-4-yl)benzene; 3-(propan-2-yloxy)benzene; 3-(trifluoromethoxy)benzene; 3-(trifluoromethyl)benzene ;3,4-dichlorobenzene; 3,4-dimethoxybenzene; 3,5-dichlorobenzene; 3,5-dimethoxybenzene; 3,5-dimethylbenzene; 3-chloro-4-(trifluoromethyl)benzene; 3-chloro-4-methoxybenzene; 3-chloro-4-methylbenzene; 3-chloro-4-propoxybenzene; 3-chloro-5-(trifluoromethyl)benzene; 3-chloro-5-fluorobenzene; 3-chloro-5-methoxybenzene; 3-chloro-5-methylbenzene; 3-chlorobenzene; 3-ethanesulfonamidobenzene; 3-ethoxybenzene; 3-ethylbenzene; 3-fluoro-4-methoxybenzene; 3-fluoro-4-methylbenzene; 3-fluoro-4-propoxybenzene; 3-fluoro-5-(2-methylpropoxy)benzene; 3-fluoro-5-methoxybenzene); 3-fluoro-5-methylbenzene; 3-fluorobenzene; 3-methanesulfonamidobenzene; 3-methanesulfonylbenzene; 3-methoxybenzene; 3-methylbenzene; 3-phenylbenzene; 3-propoxybenzene; 4-(1-methyl-1H-indazole; 4-(2-methylpyridine; 4-(ethoxymethyl)benzene; 4-(morpholin-4-yl)benzene; 4-(propan-2-yloxy)benzene; 4-(trifluoromethoxy)benzene; 4-(trifluoromethyl)benzene; 4-chloro-2-ethoxybenzene; 4-chloro-2-methoxybenzene; 4-chloro-3-(trifluoromethyl)benzene; 4-chloro-3-methoxybenzene; 4-chlorobenzene; 4-ethoxy-3-fluorobenzene; 4-ethoxybenzene; 4-fluoro-3-methylbenzene; 4-fluorobenzene; 4-methanesulfonylbenzene; 4-methoxy-3,5-dimethylbenzene; 4-methoxy-3-methylbenzene; 4-methylpyridine; 4-phenylbenzene; 5-(pyrrolidin-l-yl)pyridine; 5-chloro-2-ethoxybenzene; 5-chloro-2-methoxybenzene; 5-fluoro-2-methoxybenzene; 5-fluoro-2-methylbenzene; 5-methoxypyridine; 5-methylpyridine; 5-methylthiophene; 6-(dimethylamino)pyridine; 6-methoxynaphthalene; 6-methylpyridine; 8-oxa-3-azabicyclo[3.2.1]octane; 8-oxatricyclo[7.4.0.0 2 , 7 ]trideca-1(13),2,4,6,9,11-hexaene; isoquinoline; morpholin-4-yl; naphthalene; phenoxathiine; phenyl; pyridin-3-yl; pyridine; and quinoline.

14. A compound selected from the group consisting of:

(2E)-N-(4-{[3-fluoro-5-(2-methylpropoxy)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-fluoro-4-propoxybenzene)sulfonyl]phenyl}-3- (pyridin-3-yl)prop-2-enamide;

4-(phenoxathiine-4-sulfonyl)phenyl]-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(2,5-dichlorobenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

N-ethyl-3-({4-[(2E)-3-(pyridin-3-yl)prop-2-enamido]benzene}sulfonyl)benzamide;

4-(2H-1,3-benzodioxole-5- sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

4-(2,3-dihydro-1-benzofuran-7- sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-fluoro-3-methylbenzene)sulfonyl]phenyl}-3 -(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(2-methoxybenzene)sulfonyl]phenyl}-3- (pyridin-3-yl)prop-2-enamide 4-(2-methylpyridine-3-sulfonyl)phenyl]-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

4-(naphthalene-1-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-fluoro-4-methoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-chlorobenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

N-ethyl-4-({4-[(2E)-3- (pyridin-3-yl)prop-2-enamido]benzene}sulfonyl)benzamide;

(2E)-N-{4-[(3-chloro-4-propoxybenzene)sulfonyl]phenyl}-3 -(pyridin-3-yl)prop-2-enamide;

(2E)-N- (4-{[3-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(5-chloro-2-ethoxybenzene)sulfonyl]phenyl}-3- (pyridin-3-yl)prop-2-enamide;

4-(1-methyl-1H-indazole-6-sulfonyl)phenyl]-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-chloro-4-methoxybenzene)sulfonyl]phenyl}-3- (pyridin-3-yl)prop-2-enamide;

(2E)-3- (pyridin-3-yl)-N-(4-{[4-(trifluoromethyl)benzene]sulfonyl}phenyl)prop-2-enamide;

(2E)-3- (pyridin-3-yl)-N-(4-{[3-(trifluoromethoxy)benzene]sulfonyl}phenyl)prop-2-enamide;

(2E)-N-(4-{[2-methoxy-5-(propan-2-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

4-(1H-indole-7- sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-3-(pyridin-3-yl)-N-{4-[5-(pyrrolidin-1-yl)pyridine-3-sulfonyl]phenyl}prop-2-enamide;

(2E)-N- (4-{[3-chloro-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

4-(1-methyl-1H-indole-2-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-3-(pyridin-3-yl)-N-(4-{[4-(trifluoromethoxy)benzene]sulfonyl}phenyl)prop-2-enamide;

(2E)-N-{4-[(3-chloro-4-methylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

4-(6-methoxynaphthalene-2-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-ethoxy-3-fluorobenzene)sulfonyl]phenyl}-3 -(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-fluoro-5-methylbenzene)sulfonyl]phenyl}-3 -(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3,4-dimethoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[4-(morpholin-4-yl)piperidine-1 -sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-3-(pyridin-3-yl)-N-[4-(quinoline-3-sulfonyl)phenyl]prop-2-enamide;

(2E)-N-(4-{[2-chloro-5-(trifluoromethoxy)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-phenylbenzene)sulfonyl]phenyl }-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-fluorobenzene)sulfonyl]phenyl }-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-methylbenzene)sulfonyl]phenyl }-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3,5-dimethoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

4-(5-methoxypyridine-3- sulfonyl)phenyl]-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-chlorobenzene)sulfonyl]phenyl}-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-chloro-5-methoxybenzene)sulfonyl]phenyl}-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-methanesulfonamidobenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

4-(5-methylpyridine-3-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[3-(methoxymethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(4-{8-oxa-3-azabicyclo [3.2.1]octane-3-sulfonyl}phenyl)methyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3,5-dimethylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(5-fluoro-2-methylbenzene)sulfonyl]phenyl}-3 -(pyridin-3-yl)prop-2-enamide;

(2E)-3-(pyridin-3-yl)-N-(4-{[2-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)prop-2-enamide;

4-(6-methylpyridine-3-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

4-(isoquinoline-4-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

3-chloro-N,N-diethyl-5-({4-[(2E)-3-(pyridin-3-yl)prop-2-enamido]benzene}sulfonyl)benzamide;

(2E)-N-{4-[(4-methoxy-3-methylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

4-(benzenesulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

N-cyclopentyl-3-({4-[(2E)-3-(pyridin-3-yl)prop-2-enamido]benzene}sulfonyl)benzamide;

(2E)-N-{4-[(3-methanesulfonylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[2-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl }-3-(pyridin-3-yl)prop-2-enamide;

(2E)-3-(pyridin-3-yl)-N-(4-{[2-(trifluoromethoxy)benzene]sulfonyl}phenyl)prop-2-enamide;

N-(propan-2-yl)-3-({4-[(2E)-3- (pyridin-3-yl)prop-2-enamido]benzene}sulfonyl)benzamide;

(2E)-3- (pyridin-3-yl)-N-(4-{[3-(trifluoromethyl)benzene]sulfonyl}phenyl)prop-2-enamide;

4-(1-benzothiophene-7-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[2-(dimethylamino)pyrimidine-5-sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-ethoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-fluoro-4-methylbenzene)sulfonyl]phenyl }-3 -(pyridin-3-yl)prop-2-enamide;

4-(1H-indole-4-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{[4-(benzenesulfonyl)phenyl]methyl }-3-(pyridin-3-yl)prop-2-enamide;

(2E)-3-(pyridin-3-yl)-N-[4-(quinoline-8-sulfonyl)phenyl]prop-2-enamide;

(2E)-N-(4-{[2-methoxy-5-(trifluoromethoxy)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-ethoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

4-(5-methylthiophene-2-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-chloro-3-methoxybenzene)sulfonyl]phenyl}-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[2-methoxy-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

N-(2-methylpropyl)-3-({4-[(2E)-3-(pyridin-3 -yl)prop-2-enamido]benzene}sulfonyl)benzamide;

N-cyclopropyl-3-({4-[(2E)-3-(pyridin-3-yl)prop-2-enamido]benzene}sulfonyl)benzamide;

(2Z)-N-[4-(benzenesulfonyl)phenyl]-2-fluoro-3- (pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-fluoro-5-methoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N- (4-{[2-methyl-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

4-(1-propyl-1H-pyrazole-4-sulfonyl)phenyl1-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[4-(ethoxymethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-methanesulfonylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-methoxy-3,5-dimethylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(5-chloro-2-methoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[4-(morpholin-4-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-3-(pyridin-3-yl)-N-[4-(pyridine-3-sulfonyl)phenyl]prop-2-enamide;

(2E)-N-(4-{[3-(propan-2-yloxy)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-chloro-2-methoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N- (4-{[3-(2-methylpropoxy)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-ethylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-3-(pyridin-3-yl)-N-[4-(quinoline-6-sulfonyl)phenyl]prop-2-enamide;

(2E)-N-{4-[(3-chloro-5-methylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(2-methoxy-5-methylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide

(2E)-N-{4-[(3,5-dichlorobenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[3-(morpholin-4-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[3-(3,5-dimethyl-1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-propoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{8-oxatricyclo[7.4.0.0 2 , 7 ]trideca-1(13),2,4,6,9, 11-hexaene-6-sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(5-fluoro-2-methoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

4-(1-methyl-1H-indazole-5-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[4-(propan-2-yloxy)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[3-chloro-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-3-(pyridin-3-yl)-N-{4-[(3-sulfamoylbenzene)sulfonyl]phenyl }prop-2-enamide;

(2E)-N-{4-[(3-methoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(2-methylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

4-(2H-1,3-benzodioxole-4- sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-ethanesulfonamidobenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-fluorobenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

4-(4-methylpyridine-3-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

4-(1-methyl-1H-indazole-7-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3,4-dichlorobenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

4-(1-methyl-1H-pyrazole-4-sulfonyl)phenyl]-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[4-chloro-3-(trifluoromethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-(4-{[2-methoxy-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N- (4-{[3-(ethanesulfonyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-chloro-5-fluorobenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(4-chloro-2-ethoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

(2E)-N-{4-[(3-phenylbenzene)sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide; and

(2E)-N-{4-[6-(dimethylamino)pyridine-3-sulfonyl]phenyl}-3-(pyridin-3-yl)prop-2-enamide;

and pharmaceutically acceptable salts thereof.

15. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition of claim 15 , further comprising a chemotherapeutic agent.

17. The pharmaceutical composition of claim 16 , wherein said chemotherapeutic agent is a DNA damaging agent.

18. The pharmaceutical composition of claim 15 , further comprising a cell rescuing agent.

19. The pharmaceutical composition of claim 18 , wherein said cell rescuing agent is selected from the group consisting of nicotinamide, nicotinic acid, and nicotinamide mononucleotide.

20. The pharmaceutical composition of claim 19 , wherein said chemotherapeutic agent is selected from the group consisting of: cytotoxic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, the epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, tipifarnib, R115777, L778,123, BMS 214662, gefitnib, erlotinib, C225, ibantinib mesylate, interferon alfa-2b, peginterferon alfa-2b, aromatase combinations, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, oxaliplatin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrol acetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Fulvestrant, Exemestane, Ifosfomide, Rituximab, Campath, leucovorin, and dexamethasone, bicalutamide, carboplatin, chlorambucil, letrozole, megestrol, and valrumbicin.

21. A method to treat a condition caused by an elevated level of NAMPT in a patient by administering a therapeutically effective amount of at least one compounds of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said condition is a cancer.

22. The method of claim 21 , wherein said condition is ovarian cancer.